1. Home
  2. FSP vs ACRV Comparison

FSP vs ACRV Comparison

Compare FSP & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.52

Market Cap

72.4M

Sector

Real Estate

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.83

Market Cap

67.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSP
ACRV
Founded
1981
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.4M
67.2M
IPO Year
2001
2022

Fundamental Metrics

Financial Performance
Metric
FSP
ACRV
Price
$0.52
$1.83
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
1.2M
317.4K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
6.34%
N/A
EPS Growth
15.69
15.13
EPS
N/A
N/A
Revenue
$107,162,000.00
N/A
Revenue This Year
$17.91
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$1.20
52 Week High
$1.82
$3.56

Technical Indicators

Market Signals
Indicator
FSP
ACRV
Relative Strength Index (RSI) 41.87 63.74
Support Level $0.50 $1.73
Resistance Level $0.71 $1.86
Average True Range (ATR) 0.04 0.10
MACD -0.01 0.04
Stochastic Oscillator 6.01 98.59

Price Performance

Historical Comparison
FSP
ACRV

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: